Jardiance and Bupropion Interaction: What Patients and Clinicians Need to Know

Are Jardiance and Bupropion Safe to Take Together?

For most patients, empagliflozin and bupropion can be co-prescribed with appropriate monitoring. No pharmacokinetic study has identified a direct interaction because empagliflozin is cleared almost entirely by uridine diphosphate-glucuronosyltransferases (UGTs), not by CYP2D6, the enzyme bupropion inhibits most potently. The indirect pharmacodynamic risks, including volume depletion, electrolyte shifts, and lowered seizure threshold, deserve careful attention before and during co-administration.

The FDA prescribing information for empagliflozin confirms that the drug is "primarily eliminated by glucuronidation" and that no clinically meaningful CYP-mediated interactions have been identified in dedicated drug-interaction studies [1]. Bupropion's label, by contrast, carries a boxed warning for seizure risk and lists the drug as "a CYP2D6 inhibitor" that can raise plasma concentrations of co-administered CYP2D6 substrates by two- to fivefold [2].

Because empagliflozin is not a CYP2D6 substrate, bupropion's inhibitory effect does not alter empagliflozin exposure in any clinically meaningful way.

How Each Drug Is Metabolized

Understanding why a direct interaction is unlikely requires a brief look at the metabolic pathways of both agents.

Empagliflozin Pharmacokinetics

Empagliflozin reaches peak plasma concentration roughly 1.5 hours after an oral dose [1]. It is glucuronidated by UGT1A3, UGT1A8, UGT1A9, and UGT2B7 into three inactive glucuronide metabolites. Renal excretion of unchanged drug accounts for about 27% of total clearance [1]. P-glycoprotein (P-gp) does transport empagliflozin, but bupropion is not a P-gp inhibitor, so that pathway is also unaffected.

Protein binding is approximately 86%, and the mean terminal half-life is 12.4 hours, supporting once-daily dosing [1].

Bupropion Pharmacokinetics

Bupropion is metabolized primarily by CYP2B6 to its active metabolite hydroxybupropion [2]. Hydroxybupropion reaches plasma concentrations three to fivefold higher than the parent compound and is itself a potent CYP2D6 inhibitor [2]. The FDA label states that a single 75 mg dose of bupropion increased desipramine AUC by fivefold and Cmax by twofold, illustrating the magnitude of CYP2D6 inhibition possible.

Bupropion's half-life is 21 hours (immediate-release) and up to 33 hours for the extended-release formulation, meaning CYP2D6 inhibition persists well beyond each dose.

Why the Pathways Do Not Collide

Empagliflozin is a UGT substrate. Bupropion inhibits CYP2D6. These are entirely separate enzyme systems. No dose adjustment of empagliflozin is warranted based on co-administration with bupropion alone [1].

Pharmacodynamic Risks That Do Matter

Even without a pharmacokinetic collision, two indirect pharmacodynamic concerns warrant structured monitoring.

Seizure Threshold and Fluid/Electrolyte Status

Bupropion lowers seizure threshold in a dose-dependent manner. The FDA label notes that seizure incidence is approximately 0.1% at doses up to 300 mg/day and rises to about 0.4% at 400 mg/day [2]. Several case reports have linked severe hyponatremia and hypokalemia to SGLT2 inhibitor-related volume depletion, and electrolyte disturbances are a well-recognized seizure precipitant.

A 2022 systematic review published in Diabetes, Obesity and Metabolism found that SGLT2 inhibitors were associated with a pooled rate of clinically significant volume depletion of 1.4% versus 0.6% for placebo, with the risk highest in patients older than 75 or taking concurrent diuretics [3]. Patients on bupropion who develop hyponatremia from empagliflozin-related dehydration may face a compounded seizure risk.

Practical guidance: check a basic metabolic panel at baseline and at 4 to 6 weeks after starting both drugs. Electrolyte repletion should be prompt.

Euglycemic Diabetic Ketoacidosis

Empagliflozin suppresses renal glucose reabsorption by blocking the SGLT2 transporter, which can shift metabolism toward ketone production even when blood glucose appears near-normal [4]. The FDA issued a safety communication in 2015 noting reports of euglycemic DKA with SGLT2 inhibitors, a condition that may not be caught by standard glucose monitoring alone [4].

A pooled analysis of EMPA-REG OUTCOME and other empagliflozin trials estimated euglycemic DKA at 0.16 per 100 patient-years [5]. Bupropion does not directly raise DKA risk, but patients using bupropion for weight management who also reduce carbohydrate intake aggressively may increase ketone production synergistically.

Counsel patients to check ketones if they experience nausea, vomiting, or abdominal pain even when glucose reads below 250 mg/dL.

Bupropion as a Weight-Management Agent in Diabetes

Bupropion is prescribed both for depression and, in combination with naltrexone (Contrave), as an FDA-approved weight-loss medication. The COR-I trial (N=1,742) showed that naltrexone 32 mg plus bupropion 360 mg produced 6.1% mean weight loss at 56 weeks versus 1.3% for placebo (P<0.001) [6]. Bupropion monotherapy at 400 mg SR produced 7.2% weight loss at 24 weeks in a separate randomized controlled trial [7].

Patients with type 2 diabetes taking empagliflozin often have weight-loss goals. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin 10 mg reduced body weight by a mean of 2.6 kg versus 0.4 kg placebo at 206 weeks [8]. Co-prescribing bupropion for additional weight reduction is therefore clinically rational in appropriately selected patients, provided the risks outlined above are managed.

Overlapping Cardiovascular Benefits

Empagliflozin reduced cardiovascular death by 38% versus placebo in EMPA-REG OUTCOME (hazard ratio 0.62, 95% CI 0.49 to 0.77, P<0.001) [8]. Bupropion's cardiovascular safety data are more nuanced. A large observational study published in the BMJ (N=238,963 antidepressant initiators) found no significant increase in serious cardiac events with bupropion compared with SSRIs, though the absolute risk picture in patients with established cardiovascular disease warrants individual assessment [9].

Appetite Suppression and Hypoglycemia

Both drugs can reduce appetite, though by different mechanisms. Empagliflozin causes urinary caloric loss of roughly 70 to 80 grams of glucose per day at steady state [1]. Bupropion suppresses appetite centrally via dopamine and norepinephrine reuptake inhibition. In patients also taking insulin or sulfonylureas, this combined appetite suppression can reduce caloric intake enough to precipitate hypoglycemia.

The American Diabetes Association 2024 Standards of Care recommend proactive reduction of insulin or secretagogue doses when initiating agents that reduce caloric intake significantly [10].

Bupropion as a CYP2D6 Inhibitor: Which Co-Medications Are Actually Affected

Because patients on empagliflozin often take multiple medications, clinicians should audit the full medication list for true CYP2D6 substrates that bupropion WILL affect.

High-Risk CYP2D6 Substrates to Review

Several drugs commonly prescribed alongside empagliflozin are CYP2D6 substrates. These include metoprolol, carvedilol, codeine, tramadol, and certain tricyclic antidepressants. Bupropion co-administration can double or triple plasma concentrations of these agents [2].

For metoprolol specifically, a pharmacokinetic study showed that bupropion 150 mg twice daily increased metoprolol AUC by 4.5-fold [2]. Patients on metoprolol for heart failure or post-MI cardioprotection should have their heart rate and blood pressure monitored closely when bupropion is added.

Codeine and Tramadol: A Safety Alert

Bupropion inhibits the CYP2D6-mediated conversion of codeine to morphine and of tramadol to O-desmethyltramadol. The clinical result is reduced analgesic effect alongside accumulation of parent compound. The FDA label for tramadol warns that CYP2D6 inhibition increases risk of seizure and serotonin syndrome [2]. This risk is independent of empagliflozin but becomes relevant because clinicians prescribing bupropion for diabetic patients may also consider tramadol for peripheral neuropathy pain.

Patient Populations That Require Extra Caution

Older Adults

The FDA empagliflozin label notes that patients 75 years or older had higher rates of volume depletion-related adverse events in clinical trials [1]. Older adults are also at greater baseline seizure risk and more likely to be on CYP2D6-substrate medications. In this group, starting empagliflozin at 10 mg (rather than titrating immediately to 25 mg) and keeping bupropion at or below 300 mg/day is a reasonable conservative approach.

Patients With a Seizure History

The FDA label for bupropion contraindicates its use in patients with a current or prior seizure disorder [2]. Empagliflozin's volume-depleting and electrolyte-altering effects could lower the seizure threshold further in predisposed individuals. In this population, the combination should be avoided or used only after specialist neurology input.

Patients on Insulin or Sulfonylureas

Adding empagliflozin to insulin or sulfonylurea therapy increases hypoglycemia risk. The EMPA-REG OUTCOME trial reported symptomatic hypoglycemia in 27.9% of patients on background insulin who received empagliflozin, compared with 24.2% on placebo [8]. Bupropion-related appetite suppression adds a further caloric-reduction variable. Proactive dose reduction of the secretagogue or insulin is often appropriate.

A Structured Pre-Prescription Checklist

Before co-prescribing empagliflozin and bupropion, a clinician should confirm the following five points:

1. No active seizure disorder or prior seizure history (bupropion contraindication).
2. Baseline electrolytes documented; sodium and potassium within normal range.
3. Bupropion dose at or below 300 mg/day unless clinical need is compelling.
4. Full medication list reviewed for CYP2D6 substrates (metoprolol, carvedilol, codeine, tramadol, tricyclics).
5. Patient instructed to check urine ketones with symptoms of nausea, vomiting, or abdominal pain.

Monitoring Protocol After Initiation

Standard monitoring after co-initiation should follow a defined schedule rather than waiting for symptoms.

At baseline: fasting glucose, HbA1c, basic metabolic panel (sodium, potassium, creatinine, bicarbonate), blood pressure, and body weight.

At 2 weeks: blood pressure and symptom review (dizziness, dry mouth, polyuria).

At 4 to 6 weeks: repeat basic metabolic panel to detect early electrolyte drift. Check HbA1c trajectory if needed.

At 3 months: full metabolic panel, HbA1c, weight, and review of any neurological symptoms.

Annually: renal function (eGFR), urine albumin-to-creatinine ratio, and reassessment of bupropion dose necessity.

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends reassessing cardiovascular risk factors every 3 months during the first year of any weight-loss pharmacotherapy, a schedule that aligns well with the monitoring plan above [11].

Drug Interaction Severity Classification

Major DDI databases classify the empagliflozin-bupropion pair differently depending on their methodology.

Lexicomp assigns a "C" rating (monitor therapy) based on pharmacodynamic overlap rather than pharmacokinetic interaction. Drugs.com rates it as a "moderate" interaction, citing bupropion's seizure-lowering potential as the primary concern. Neither database identifies a mechanism that would require dose adjustment of empagliflozin itself.

The FDA drug interaction guidance document for SGLT2 inhibitors, last updated in the empagliflozin label revision of 2023, does not list bupropion as a drug requiring a specific warning or dose modification [1].

Clinicians should interpret "moderate" DDI ratings in this pair as a prompt for structured monitoring rather than a contraindication.

Practical Patient Counseling Points

Patients co-prescribed these two medications deserve clear instructions on three topics.

First, hydration. Empagliflozin increases urine output. Patients should aim to drink at least 2 liters of water per day and avoid prolonged fasting or alcohol binges, which compound dehydration. A published pharmacokinetic analysis showed that volume depletion sufficient to raise serum creatinine by more than 20% from baseline occurred in 1.6% of empagliflozin-treated patients in clinical trials [1].

Second, seizure awareness. Patients should know that bupropion carries a dose-dependent seizure risk and that dehydration or electrolyte loss can further lower the threshold. Any episode of unusual muscle jerking, blackout, or witnessed convulsion warrants immediate medical evaluation and temporary discontinuation of bupropion pending workup.

Third, ketone awareness. The instruction "check ketones if you feel sick, even if your glucose is normal" is not standard patient education for most type 2 diabetes patients, but it is appropriate for those on SGLT2 inhibitors. Urine ketone strips are available over-the-counter and cost less than $15 per 50-strip container.